Cancer Biological Therapy Companies

AstraZeneca and Merck expand collaboration on Lynparza (olaparib)  The two pharma giants signed a new agreement to co-develop and commercialize Lynparza for additional cancer indications, potentially expanding its reach to a wider range of patients.

Roche receives EU approval for Tecentriq (atezolizumab) and Avastin (bevacizumab) combination for liver cancer approval marks a significant step forward in treating advanced hepatocellular carcinoma, offering a new option for patients with limited treatment options.

Novartis secures EU approval for Kisqali (ribociclib) in combination with letrozole for advanced breast cancer approval provides a new hormonal therapy option for postmenopausal women with HR+/HER2- advanced breast cancer, potentially improving treatment outcomes.

Sanofi expands CAR-T cell therapy portfolio with acquisition of CellPoint Therapeutics move strengthens Sanofi's position in the promising field of CAR-T therapy, which offers personalized treatment options for various cancers

List of EMEA Cancer Biological Therapy Key Companies in the Market

• Bayer AG


• Novartis AG


• Johnson and Johnson


• Pfizer Inc.


• Bristol-Myers Squibb Company


• Amgen Inc.


• AstraZeneca plc.


• Celgene Corporation


• Engeneic Ltd.


• Eli Lily and Company


• Merck and Co.


• Hoffmann-La Roche Ag.


• Teva Pharmaceutical